Psoriasis-related juvenile idiopathic arthritis

This study is testing a drug called secukinumab, given as an IV infusion, in 20 children aged 2 to 17 with juvenile psoriatic arthritis. The main goals are to see how the drug moves through the body and to check its safety over up to 6 years. This is an early-stage trial, so it f…

This Phase 3 study tests whether the drug apremilast (Otezla) can safely reduce joint inflammation and pain in children aged 5 to 17 with active juvenile psoriatic arthritis. About 60 participants will receive either apremilast or a placebo pill for 16 weeks. The main goal is to …

This study tests a drug called risankizumab in children with juvenile psoriatic arthritis, a condition causing joint pain and swelling. About 40 kids will receive either risankizumab or the standard drug adalimumab for 24 weeks, with responders continuing for up to 2 years. The g…

This study is checking the long-term safety of guselkumab, a biologic drug given as a shot, in children with moderate to severe Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis. About 196 kids who already completed a prior guselkumab study and benefited from i…

This study tests a drug called deucravacitinib in children aged 5 to 17 with active juvenile psoriatic arthritis, a condition causing joint pain and swelling. The trial aims to see if the drug can control the disease and prevent flare-ups. About 60 participants will receive eithe…

This study looks at the safety and effectiveness of the drug Xeljanz in children aged 2 to 17 with active juvenile idiopathic arthritis or juvenile psoriatic arthritis. It is an observational study in Korean clinics, meaning doctors prescribe the drug as usual and researchers mon…

This study tests a drug called bimekizumab in children aged 2 to 17 with specific types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). The goal is to see how the drug moves through the body and if it is safe. About 40 children will take par…

This study looks at the long-term safety of the drug apremilast in children aged 2 and older with Behçet's disease (causing mouth ulcers) or aged 5 and older with juvenile psoriatic arthritis. About 48 kids who finished a previous study will take apremilast for up to 52 more week…